Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in Enterobacterales

被引：8
|
作者：
Sadek, Mustafa [1 ,2 ]
Duran, Juan Bosch [1 ]
Poirel, Laurent [1 ,3 ]
Nordmann, Patrice [1 ,3 ,4 ]
机构：
[1] Univ Fribourg, Fac Sci & Med, Med & Mol Microbiol, Fribourg, Switzerland
[2] South Valley Univ, Fac Vet Med, Dept Food Hyg & Control, Qena, Egypt
[3] Univ Fribourg, Swiss Natl Reference Ctr Emerging Antibiot Resista, Fribourg, Switzerland
[4] Univ Lausanne, Univ Hosp Ctr, Inst Microbiol, Lausanne, Switzerland
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年 / 67卷 / 05期
基金：
瑞士国家科学基金会;
关键词：
minor carbapenemases; SME; Enterobacterales; imipenem-relebactam; FRI; NMC-A; carbapenemase;
D O I：
10.1128/aac.00078-23
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The in vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam, and cefiderocol was evaluated against both clinical and isogenic enterobacterial isolates producing carbapenemases of the SME, NmcA, FRI, and IMI types. Ceftazidime-avibactam and meropenem-vaborbactam showed the highest activity against all tested isolates; imipenem-relebactam showed only moderate activity. All isolates remained susceptible to cefiderocol. Furthermore, avibactam and vaborbactam have greater inhibitory activity than relebactam against the tested carbapenemases. Overall, ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol were the most effective therapeutic options for treating infections caused by the tested minor carbapenemase producers.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] In Vitro and In Vivo Development of a β-Lactam-Metallo-β- Lactamase Inhibitor: Targeting Carbapenem-Resistant Enterobacterales
    Peters, Byron K.
    Reddy, Nakita
    Shungube, Mbongeni
    Girdhari, Letisha
    Baijnath, Sooraj
    Mdanda, Sipho
    Chetty, Lloyd
    Ntombela, Thandokuhle
    Arumugam, Thilona
    Bester, Linda A.
    Singh, Sanil D.
    Chuturgoon, Anil
    Arvidsson, Per I.
    Maguire, Glenn E. M.
    Kruger, Hendrik G.
    Naicker, Tricia
    Govender, Thavendran
    ACS INFECTIOUS DISEASES, 2023, 9 (03): : 486 - 496
  • [42] In vitro efficacy of β-lactam/β-lactamase inhibitor combinations against bacteria involved in mixed infections
    Finegold, SM
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1999, 12 : S9 - S14
  • [43] USE OF BETA-LACTAM/BETA-LACTAMASE-INHIBITOR COMBINATIONS AS ANTIMYCOBACTERIAL AGENTS
    PRABHAKARAN, K
    HARRIS, EB
    RANDHAWA, B
    ADAMS, LB
    WILLIAMS, DL
    HASTINGS, RC
    MICROBIOS, 1993, 76 (309) : 251 - 261
  • [44] Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
    van Duin, David
    Bonomo, Robert A.
    CLINICAL INFECTIOUS DISEASES, 2016, 63 (02) : 234 - 241
  • [45] Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens
    Karaiskos, Ilias
    Galani, Irene
    Souli, Maria
    Giamarellou, Helen
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (02) : 133 - 149
  • [46] Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations
    Tandar, Sebastian T.
    Aulin, Linda B. S.
    Leemkuil, Eva M. J.
    Liakopoulos, Apostolos
    van Hasselt, J. G. Coen
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (03) : 199 - 211
  • [47] BETA-LACTAM BETA-LACTAMASE INHIBITOR COMBINATIONS FOR ORAL-ADMINISTRATION
    FRANCIOLLI, M
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1991, 121 (39) : 1399 - 1407
  • [48] In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors
    Shields, Ryan K.
    Kline, Ellen G.
    Squires, Kevin M.
    Van Tyne, Daria
    Doi, Yohei
    JAC-ANTIMICROBIAL RESISTANCE, 2023, 5 (05):
  • [49] Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature
    Meini, Simone
    Viaggi, Bruno
    Tascini, Carlo
    INFECTION, 2021, 49 (03) : 411 - 421
  • [50] Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature
    Simone Meini
    Bruno Viaggi
    Carlo Tascini
    Infection, 2021, 49 : 411 - 421
12345